The installation of the Illumina NextSeq 2000 sequencing platform at the Champalimaud Foundation marks a new step in strengthening precision oncology in Portugal, placing cutting-edge technology at the service of cancer research and treatment.
The Champalimaud Foundation, internationally recognised for excellence in scientific research and cancer care, is now working with Illumina technology, a global leader in genomics. The installation of the new NextSeq 2000 platform by Quilaban further consolidates this collaboration, enhancing sequencing capacity and support for precision medicine in Portugal.
This next-generation solution will enable faster molecular diagnostics, deeper translational research and the development of more targeted and effective therapies.
For Quilaban, this installation represents an important milestone in its mission to promote scientific and technological innovation in healthcare. The NextSeq 2000 combines speed, accuracy and flexibility, meeting the growing demands of modern oncology.
The Champalimaud Foundation now benefits from state-of-the-art infrastructure that strengthens its scientific and clinical capabilities in precision oncology, contributing to placing innovation at the service of life.